HIV/AIDS Adverse Drug Reaction
Atazanavir/ritonavir combination has fewer adverse effects than lopinavir/ritonavir
Published in AIDS Weekly, May 29th, 2006
According to recent research from England, "In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up to 96 weeks are presented."
"BMS Study 045 was an open-label, randomized, multinational trial of HIV-infected patients with virologic failure on two or more prior HAART regimens designed to evaluate the efficacy and safety of ATV/RTV (300/100 mg) QD and LPV/RTV...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-05-29)
More Articles from AIDS Weekly
- AIDS-Related Kaposi Sarcoma
MMP inhibitor COL-3 active and well tolerated in AIDS-related Kaposi sarcoma - HIV/AIDS Drug-Drug Interaction
Pravastatin and nelfinavir coadministration reduces pravastatin plasma levels - HIV/AIDS Epidemiology
Emerging pediatric HIV epidemic related to migration in low incidence countries - HIV/AIDS Pathogenesis
HIV-1 progression affected by nonsense mutation 428G->A in fucosyltransferase FUT2 gene - Business & Finance
Cylex announces first quarter revenues increased 74% over Q1 2005 - Business & Finance
Idenix Pharmaceuticals reports unaudited first-quarter revenues of $13.1 million - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
